Insider Transaction Report for Bicara Therapeutics Inc.

This filing details a stock option grant to Kiran Mazumdar-Shaw, a director at Bicara Therapeutics Inc. (BCAX). On June 9, 2026, 19,475 stock options were granted with an exercise price of $20.56 per share. These options vest upon the earlier of June 9, 2027, or the next Annual Meeting of Stockholders, contingent upon continued service. The underlying security is common stock, and following the transaction, 19,475 shares are held. The filing was made on June 10, 2026, by Ryan Cohlhepp, acting as Attorney-in-Fact for the reporting person. This transaction is classified as an acquisition of a derivative security.